Advancing Scientific Frontiers: M20 Genomics' VITA Platform at Duke University School of Medicine

Durham, NC – M20 Genomics is pleased to announce the installation of its VITA Single-Cell Full-Length Transcriptome Platform in our collaboration labs at Duke University School of Medicine, significantly enhancing the research tools available to local teams. This strategic partnership with our esteemed collaborating research groups substantially advances the scientific resources at Duke University School of Medicine, enabling precise transcriptomic profiling at the single-cell level and providing detailed insights into cellular mechanisms.

Fully operational VITA platform in on of our collaboration labs at Duke University School of Medicine.

Unlocking New Frontiers in Single-Cell Analysis with Enhanced Capabilities

Following the successful deployment of the VITA platform, our technical team has provided comprehensive training for Duke researchers. This training encompassed experimental protocols, instrument and reagent usage, and proficiency in data analysis software, ensuring optimal utilization of the platform's advanced capabilities. The integration of the VITA platform further strengthens the research infrastructure at Duke University School of Medicine, facilitating single-cell transcriptomic profiling across diverse sample types.

Duke researcher conducting single-cell RNA sequencing with VITA platform.

Utilizing innovative random primer-based M20 Seq technology, the VITA platform offers unparalleled sample coverage. It accommodates a wide range of sample types, including fresh, frozen, and FFPE samples. Its unique capabilities extend to a diverse array of biological species, from eukaryotes to bacteria, and it is particularly designed for processing complex samples such as gut microbiota—all with a single platform. The adoption of the VITA platform further enhances the rich research facilities at Duke University School of Medicine, enabling researchers to conduct comprehensive studies across various biological systems with highest precision and efficiency.

This strategic collaboration underscores M20 Genomics' dedication to fostering global academic cooperation and excellence in research and aims to harness cutting-edge technologies and research expertise for groundbreaking discoveries that profoundly impact our understanding of human health and disease.

About Duke University School of Medicine

Established in 1925 in Durham, North Carolina, Duke University School of Medicine stands as a global leader in health professions and biomedical education, clinical care, and biomedical research. Renowned for its steadfast commitment to improving clinical outcomes through groundbreaking research, the school cultivates collaborations among its diverse departments and global partners. Leveraging collective expertise and resources, Duke School of Medicine is addresses pressing global health challenges with innovation and compassion.

About M20 Genomics

M20 Genomics is a rapidly growing life science technology company dedicated to pushing the boundaries of single-cell and spatial technologies. Our mission is to empower our customers by overcoming technological barriers in cutting-edge single-cell and spatial technologies, unraveling mysteries in life science, and driving advancements in disease diagnosis and treatment. With M20 Seq technology, we have pioneered the world's first high-throughput full-length single-cell technology sequencing using random primers, along with our VITA product line for single-cell transcriptome sequencing. In addition, our M20 Spatial technology, utilizing random primers and paired with our NATA spatial transcriptome product line, provides the first spatial full-transcriptome solution across various sample types. To learn more about our transformative technologies, visit the M20 Genomics website or follow us on LinkedIn or X.